Biomarkers in patients with heart failure and central sleep apnoea: findings from the SERVE‐HF trial - Université de Lorraine Accéder directement au contenu
Article Dans Une Revue ESC Heart Failure Année : 2020

Biomarkers in patients with heart failure and central sleep apnoea: findings from the SERVE‐HF trial

Holger Woehrle
Martin R Cowie
  • Fonction : Auteur
  • PersonId : 913743

Résumé

Aims: The Treatment of Sleep-Disordered Breathing with Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients with Heart Failure trial investigated the effects of adaptive servo-ventilation (ASV) (vs. control) on outcomes of 1325 patients with heart failure and reduced ejection fraction (HFrEF) and central sleep apnoea (CSA). The primary outcome (a composite of all-cause death or unplanned HF hospitalization) did not differ between the two groups. However, all-cause and cardiovascular (CV) mortality were higher in the ASV group. Circulating biomarkers may help in better ascertain patients’ risk, and this is the first study applying a large set of circulating biomarkers in patients with both HFrEF and CSA.Methods and results: Circulating protein-biomarkers (n = 276) ontologically involved in CV pathways, were studied in 749 (57% of the trial population) patients (biomarker substudy), to investigate their association with the study outcomes (primary outcome, CV death and all-cause death). The mean age was 69 ± 10 years, and > 90% were male. The groups (ASV vs. control and biomarker substudy vs. no biomarker) were well balanced. The “best” clinical prognostic model included male sex, systolic blood pressure < 120 mmHg, diabetes, loop diuretic, cardiac device, 6-min walking test distance, and N-terminal pro BNP as the strongest prognosticators. On top of the “best” clinical prognostic model, the biomarkers that significantly improved both the discrimination (c-index) and the net reclassification index (NRI) of the model were soluble suppression of tumorigenicity 2 for the primary outcome; neurogenic locus notch homolog protein 3 (Notch-3) for CV-death and all-cause death; and growth differentiation factor 15 (GDF-15) for all-cause death only.Conclusions: We studied 276 circulating biomarkers in patients with HFrEF and central sleep apnoea; of these biomarkers, three added significant prognostic information on top of the best clinical model: soluble suppression of tumorigenicity 2 (primary outcome), Notch-3 (CV and all-cause death), and GDF-15 (all-cause death).
Fichier principal
Vignette du fichier
ESC_HF_SERVE_HF_Biomarkers.pdf (479.24 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-02571966 , version 1 (13-05-2020)

Identifiants

Citer

Joao Pedro Ferreira, Kevin Duarte, Holger Woehrle, Martin R Cowie, Karl Wegscheider, et al.. Biomarkers in patients with heart failure and central sleep apnoea: findings from the SERVE‐HF trial. ESC Heart Failure, 2020, 7 (2), pp.503-511. ⟨10.1002/ehf2.12521⟩. ⟨hal-02571966⟩
188 Consultations
90 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More